IQVIA (NYSE:IQV) Reaches New 52-Week Low – Here’s What Happened

IQVIA Holdings Inc. (NYSE:IQV)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $146.06 and last traded at $147.20, with a volume of 197303 shares trading hands. The stock had previously closed at $154.73.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Robert W. Baird dropped their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. UBS Group decreased their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Price Performance

The business’s fifty day moving average price is $189.67 and its 200 day moving average price is $203.55. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market cap of $26.86 billion, a P/E ratio of 20.35, a PEG ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock worth $3,956,087,000 after purchasing an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock worth $841,461,000 after acquiring an additional 712,958 shares during the last quarter. Geode Capital Management LLC increased its position in IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after acquiring an additional 77,981 shares during the period. Invesco Ltd. raised its stake in shares of IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after acquiring an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after purchasing an additional 59,426 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.